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grafting materials has been investigated in many studies.
Objective: The aim of this histologic study was to evaluate the efﬁcacy of PRF mixed with biphasic
calcium phosphate (BCP) on bone regeneration in surgically created bone defects.
Methods: Defects 5 mm in diameter were created in both tibias of 6 sheep. The defects were left empty
or grafted with BCP, PRF, or BCPþPRF. Animals were killed at 10, 20, and 40 days. The specimens
underwent histologic and histomorphometric analysis.
Results: None of the groups displayed any signs of necrosis. Inﬂammation was observed in all groups at
10 days; 2 specimens of PRFþBCP and all empty defects showed inﬂammatory cell inﬁltration at 20 days.
During the 40-day evaluation period, the PRFþBCP group showed the highest ratios of new bone. The
other 3 groups showed statistically similar results. In the BCP and PRFþBCP groups, the residual graft
ratios were decreased at consecutive time intervals. The difference between the 2 groups was not
statistically signiﬁcant during follow-up.
Conclusions: The current study revealed a histomorphometric increase in bone formation with the
addition of PRF to BCP in surgically created defects in sheep tibia.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Platelet-rich ﬁbrin (PRF) is an autologous ﬁbrin matrix. It was
described by Choukroun et al1 speciﬁcally for oral and maxillo-
facial surgery applications. PRF can be classiﬁed as a second-
generation platelet concentrate because it contains leukocytes
and does not require an anticoagulant.2–4 PRF use is a simple
technique. Venous blood is collected in 10-mL dry tubes and
centrifuged for 12 minutes at 2700 rpm (∼400g). After centrifu-
gation, 3 layers are obtained: red blood cells at the bottom,
acellular plasma at the top (platelet-poor plasma), and PRFr Inc.
PhD, Faculty of Dentistry,
, Fatih 34093, Istanbul.
(N. Bölükbaşı).
Open access under CC BY-NC-ND licebetween the 2 layers. It was shown that, after centrifugation,
∼97% of platelets and 50% of leukocytes of the original blood
volume were concentrated in the PRF.5 Previous studies showed
the slow release of growth factors such as transforming growth
factor β1, platelet-derived growth factor β, and vascular endothelial
growth factor, especially during the ﬁrst 7 days.6,7. Zumstein et al8
also reported that this release continued with the decrease up to
28 days. PRF can be used as the sole biomaterial9–21 or combined
with different bone substitutes.11,22–27 The use of PRF in conjunc-
tion with grafting materials would accelerate bone regeneration.
Biphasic calcium phosphate (BCP) is a commonly used syn-
thetic bone substitute comprising less soluble hydroxyapatite
(HA) and more soluble β-tricalcium phosphate (β-TCP). It is a
biocompatible, osteoconductive, and cost-effective biomaterial.
The main advantage of BCP is that its chemical composition is
similar to that of apatite in biological bone.28–30 The hard
particles of HA support the bulk of the graft material, and β-TCP
increases the replacement of its degradation products with blood
vessels and lamellar bone.31nse.
Fig. 1. Clinical view of surgically created defects. The ﬁrst 2 defects were grafted with biphasic calcium phosphate mixed with platelet-rich ﬁbrin (PRF) at a 1:1 ratio and
covered with PRF membrane. The other 2 defects were grafted with only PRF.
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in bone augmentation, none investigated the combination of
PRFþBCP. The aim of this experimental study was to evaluate
the inﬂammatory features and effectiveness of PRFþBCP combi-
nation to improve and accelerate bone regeneration in surgically
created bone defects in sheep.Methods
Animal model and surgical procedure
The study was approved by the Animal Ethical Committee of
Istanbul University (no. 2011-91). All procedures were conducted
in accordance with the Istanbul University ethical guidelines for
the treatment and welfare of experimental animals. The study was
conducted at the Istanbul University, Faculty of Veterinary Medi-
cine, Department of Surgery between January 2012 and February
2012. The study included 6 adult male sheep (age, 2–3 years;
weight, 40–50 kg).The animals were fasted for 24 hours preoper-
atively. Ceftriaxone sodium 22 mg/kg (1 g) (Iesef, Ulugay, Turkey)
was administered intramuscularly to reduce the risk of postoper-
ative infection. Surgical procedures were performed under general
anesthesia under sterile conditions. Xylazinen (0.2–0.5 mg/kg IM)
was given as premedication. Preanesthesia with 22 mg/kg IV
ketamine hydrochloride† was administered. The animals were
then intubated. General anesthesia was achieved using an intra-
venous injection of pentobarbital and maintained with isoﬂurane
1.5%–2%, administered through the endotracheal tube. Both tibias
were shaved and cleansed with 10% povidone iodine and 70%
alcohol swabs before manipulation. Skin and periosteal incisions
were created separately, and the tibias were exposed. In each tibia,
4 monocortically defects 5 mm in width and depth were prepared
with a trephine burr under saline solution irrigation at 1500 rpm.
A distance of 5 mmwas left between each defect. The ﬁrst 2 defects
on the right side of the tibia were grafted with BCP (HA-to-TCP
ratio: 60:40) (4Bone, MIS, Tel-Aviv, Israel) mixed with PRF (1:1
ratio) and covered with PRF membrane (Figure 1). The other
2 defects in the right tibia were grafted with only PRF. The defects
in the left tibia were left empty or grafted with only BCP (Figure
2). After obtaining adequate hemostasis, the periosteum was
closed with 4-0 resorbable suture (Vicryl, Ethicon, Turkey), and
the skin was closed with a skin stapler. The tibias were fastened
down to avoid fracture. The animals were given ceftriaxone
sodium 22 mg/kg twice daily (1 g, IM; Iesef) as an antibiotic for
5 days postoperatively. The animals were placed in separate cages
in a standard environment to allow the animals to live and fed a
standard diet. During the study period, the animals were exam-
ined for leg fractures, infection, and adverse reactions.n Trademark: Rompuns (Bayer, Istanbul, Turkey).
† Trademark: Ketalars (Eczacıbaşı, Istanbul, Turkey).The animals were killed at 10, 20, and 40 days (2 animals
at each time interval) using an overdose of sodium pentothal
(30 mg/kg, IV, Abbott, Istanbul, Turkey). The tibias were carefully
dissected free from soft tissues, and hard-tissue samples were
transferred into 10% buffered-formalin solution.
PRF preparation
PRF was prepared as described by Choukroun et al.1 After
administration of general anesthesia, venous blood was drawn
from the jugular vein into 10-mL tubes (Vacuette, Grenier Bio-One,
Kremsmünster, Austria) without anticoagulant. A total of 80 mL of
blood was taken from each animal. The tubes were immediately
centrifuged at 400g for 12 minutes (Process, Nice, France). After
centrifugation, 3 layers were obtained: acellular plasma (platelet
poor plasma) was concentrated at the top and was collected by
syringe (Figure 3); ﬁbrin clots and red corpuscles were removed
from the tube with a scalpel (Figure 4); a PRF clot was immedi-
ately separated from red corpuscles by tweezers. This clot was
either cut into small pieces and mixed with graft material or
pressed between 2 sterile compresses to obtain a membrane
(Figure 5).
Histologic and histomorphometric examination
Histopathologic and histomorphometric examinations were
performed by 1 blinded examiner (M.T.S.). All harvested specimens
were ﬁxed in 10% buffered formalin for 1 week. After ﬁxation, all
specimens were treated with 50% formic acid and 20% sodium
citrate solution for decalciﬁcation. The decalciﬁed specimens were
embedded in parafﬁn and cut into 3-mm-thick sections on charged
slides using a microtome (Leica Microsystemic RM 2125, Leica,
Berlin, Germany), and routine hematoxylin and eosin staining was
performed. The cutting line was started parallel to the transverse
axis of tibias at ∼4 mm away from tibia heads, where the ﬁrst
defect preparation was made. The sections were examined with a
light microscope (Olympus BX60, Tokyo, Japan). Histopathologic
images were captured at 10 and 20 magniﬁcation using the
microscope connected to a digital camera (Olympus E-330) con-
nected to a computer. Fibrosis, inﬂammation, and necrosis were
evaluated. The relative inﬂammatory intensity was scored as
follows: 0 ¼ no inﬂammation; 1 ¼ minimal inﬂammation; 2 ¼
moderate inﬂammation; 3 ¼ severe inﬂammation. For histomor-
phometric examination, 4 ﬁelds were captured at 10 magniﬁ-
cation from each histopathologic section. The pictures were
transferred to the imaging program (Olympus Soft Imaging System
Analysis). The proportions of the area occupied by newly formed
bone (NB) and residual graft materials (RG) were measured. All
measurements were conﬁned to a total area of 0.38 mm2.
Statistical analysis
Statistical analyses were performed using SPSS for Windows
(Version 10; SPSS Inc, Chicago, Illinois). Data are expressed as
Fig. 2. Clinical view of surgically created defects. The ﬁrst 2 defects were grafted with biphasic calcium phosphate, and the other 2 defects were left empty.
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compare the 4 groups at days 10, 20, and 40 in terms of
inﬂammation, new bone formation, and residual bone graft. The
Mann-Whitney U test was used for pairwise comparisons of
groups that showed signiﬁcant a difference from the Kruskal-
Wallis test.
Throughout the study period, overall differences between the
4 groups were assessed with Pillai’s Trace test for repeated
measures of the general linear model, and Bonferroni correction
was used for pairwise comparison. Differences were considered
signiﬁcant at a P value of ≤0.05.Fig. 3. Three layers were obtained after centrifugation at 400g for 12 minutes. The
ﬁbrin clot (platelet-rich ﬁbrin) was concentrated in the middle of the tube, between
the red corpuscles at the bottom and a cellular plasma (platelet poor plasma) at
the top.Results
Healing was uneventful in all animals. No complications were
observed. A total of 48 samples were evaluated.
Figures 6 through 9 show the histopathologic examination of
the groups at 10, 20, and 40 days at 10 or 20 magniﬁcation.
None of the groups displayed any signs of necrosis. In the
empty and PRF groups, ﬁbrous tissue was observed distinctly at
10 days. The PRFþBCP and BCP groups showed ﬁbrosis around
the reduced graft material, surrounded by new bone formation.
Active ﬁbrosis tissue involving primary mesenchymal cells
around new bone trabecula and graft material was observed in
all animals at 20 and 40 days. Diagnosed ﬁbrosis tissue gradually
reduced by day 40 and was replaced by new bone tissue. New
bone tissue was observed to be connected with graft material at
10 and 20 days, and apposition lines of material were observed to
be different. At day 40, bone tissue was found to be mature,
especially in surface areas of defects, and to have a cortical bone
appearance. New bone formation in trabecular structure was
observed around graft material present in the apical sides of
the defect. Osteoclastic activity was observed both in new bone
tissue and graft tissue.
Inﬂammation was observed in all groups at 10 days. Only the
empty defects (all) and 2 specimens from the PRFþBCP group
showed inﬂammatory cell inﬁltration at 20 days. At 40 days,
inﬂammation was not observed in any group. Table I shows
mean inﬂammation intensity scores. Kruskal-Wallis analysis
showed a nonsigniﬁcant difference at day 10 (χ2 ¼ 5.90, P ¼
0.12) and a signiﬁcant difference at day 20 (χ2 ¼ 11, P ¼ 0.01).Fig. 4. Fibrin clot (platelet-rich ﬁbrin) clot separated from red corpuscles by
tweezers.
Fig. 5. Fibrin clot (platelet-rich ﬁbrin) was cut into small pieces and mixed with
grafting material.
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PRFþgraft groups (Z ¼ −1.53, P ¼ 0.13).
Kruskal-Wallis analysis showed that the new bone ratio at
each time point was signiﬁcantly different between groups. Table
II shows NB for all groups and time intervals. At 10 days, the
lowest amount of NB (3.4 [0.7]) was observed in empty defects,
which was signiﬁcantly less than in the PRF and PRFþBCP groups
(Z ¼ −2.18, P ¼ 0.03 and Z ¼ −2.30, P ¼ 0.02, respectively) and
nonsigniﬁcantly less than BCP (Z ¼ −1.60, P ¼ 0.11). The mean NB
value was nearly the same in the PRF and BCP groups (7.4 [0.7%]
and 7.2 [1.6%], respectively; Z ¼ −0.44, P ¼ 0.66). Statistical
analysis showed that the defects ﬁlled with PRFþBCP mixtureFig. 6. Histopathologic evaluation of platelet-rich ﬁhad statistically higher NB (11.4 [0.7%]) than PRF- and BCP-
treated defects (Z ¼ −2.31, P ¼ 0.02; Z ¼ −2.31, P ¼ 0.02,
respectively).
In the PRFþBCP group, NB occupied 42.2 (0.9)% of the defect
volume at 20 days period (Table II). The other biomaterials and the
empty defects showed similar patterns (empty defect, 24.9 [0.8]%;
PRF, 29.5 [1.6]%; BCP group, 29.6 [1.7]%). The statistical analysis
determined the signiﬁcance between empty defects and PRF and
between empty defects and BCP (Z ¼ −2.32, P ¼ 0.02 and Z ¼
−2.07, P ¼ 0.04, respectively). No difference was found between
the defects treated with either PRF or BCP (Z ¼ −0.29, P ¼ 0.77).
At 40 days, the defects in the BCP and PRFþBCP groups were
approximately half ﬁlled with new bone (49.1 [3.1]% and 54.9
[0.8]%, There was no signiﬁcant difference between these 2 groups
(Z ¼ −1.60, P ¼ 0.11). The defects treated with PRFþBCP showed
more NB than the other 2 groups (Z ¼ −2.32, P ¼ 0.02 and Z ¼
−2.19, P ¼ 0.03 for empty and PRF groups, respectively). The
empty defect group (39.7 [3.1]%) showed values close to those of
the PRF (38.9 [4.9]%) and BCP (49.1 [3.1]%) groups, and there was
no signiﬁcant difference between these groups (Z ¼ −0.15, P ¼
0.89 and Z ¼ −1.73, P ¼ 0.08, respectively). As the 2 other time
intervals, the PRF and BCP groups did not show any difference
(P ¼ 0.11).
During the 40-day evaluation period, the PRFþBCP group
showed the highest NB ratios, whereas the other 3 groups showed
statistically similar results. Table III shows the results for the Pillai
Trace test for repeated measures of the general linear model.
Table IV shows the mean and SD of RG materials in BCP and
PRFþBCP groups. In both groups, the RG ratios were decreased at
subsequent evaluation periods. The differences between 2 groups
were not statistically signiﬁcant at 10, 20, and 40 days (P ¼ 0.25,
P ¼ 0.25, P ¼ 0.66, respectively) and also during the 40-day
follow-up (P ¼ 0.26).Discussion
Various bone substitutes have been introduced for ridge pres-
ervation, bone augmentation, and ﬁlling peri-implant defects in
oral implantology. Among the variety of grafting materials, PRF hasbrin þ graft at 10 (A), 20 (B), and 40 (C) days.
Fig. 7. Histopathologic evaluation of platelet-rich ﬁbrin at 10 (A), 20 (B), and 40 (C) days.
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and improve the healing process. In the present study, we
evaluated PRF in combination with BCP in surgically created
experimental bone defects. The results showed more new bone
formation in defects ﬁlled with PRFþBCP than BCP alone, PRF
alone, and empty defects. Also, no differences were observed in RG
values between the PRFþBCP and BCP groups.
Each bone substitute has advantages and disadvantages. Autog-
enous bone grafts are still considered to be the gold standard
because of their osteogenic, osteoconductive, and osteoinductive
properties. Nevertheless, this type of augmentation has the dis-
advantages of requiring for a second operative donor site and
having rapid resorption. Allogenic and xenografts grafts are
produced from other humans or animals, making these materialsFig. 8. Histopathologic evaluation of biphasic calciuunacceptable to some patients. These materials also involve the
risk of carrying disease. Synthetic or alloplastic grafting products
such as HA/TCP composite ceramics (BCP) therefore provide
another option. The advantages of BCP compared with autogenous
grafts are their synthetic origin, biocompatibility, osteoconductiv-
ity, unlimited quantity, and avoidance of a second surgical site.
Therefore, clinically applied BCP was preferred in the study.
The literature includes few studies using only PRF or graft
materials with different characteristics combined with PRF.
Tatullo et al23 conducted histological and clinical evaluations of
60 patients who underwent sinus lifting surgery before implant
surgery. The experimental group received bovine bone graft
material (Bio-Oss) combined with PRF, whereas the control group
received only bovine bone graft material (Bio-Oss, Geistlichm phosphate at 10 (A), 20 (B), and 40 (C) days.
Fig. 9. Histopathologic evaluation of empty defect at 10 (A), 20 (B), and 40 (C) days.
Table II
New bone formation ratios in each group at 10, 20, and 40 days. Data are
mean (SD).
Killing day Empty defect PRF BCP PRFþBCP
10 days 3.4 (0.7) 7.4 (0.7) 7.2 (1.6) 11.4 (0.7)
20 days 24.9 (0.8) 29.5 (1.6) 29.6 (1.7) 42.2 (0.9)
40 days 39.7 (3.1) 38.9 (4.9) 49.1 (3.1) 54.9 (0.8)
BCP, biphasic calcium phosphate; PRF, platelet-rich ﬁbrin.
Table III
Pairwise comparison of groups for 40-day evaluation period.
Groups P
Empty defect PRF 1.0
N. Bolukbasi et al. / Current Therapeutic Research 75 (2013) 15–2120Pharma AG, Wolhusen, Switzerland). The study made histologic
and histomorphometric evaluations on days 106, 120, and 150. The
results revealed that the good osteoconductive capacity of PRF led
to the production of new bone, even at 106 days. No implant loss
was observed at 36 (10) months. Primary implant stability,
assessed by means of resonance frequency analysis, did not show
any statistical difference between test and control groups. Ozdemir
et al9 assessed the effects of PRF on bone augmentation in an
animal model. Surgically created defects were ﬁlled with PRF, BCP,
or anorganic bovine bone (ABB) and were covered with titanium
membranes. Control groups were left empty. Histomorphometric
evaluation was carried out at 1 and 3 months. The control group
showed the least new bone formation, and similar new bone areas
were found among PRF, BCP, and ABB groups after 1 month. PRF
and ABB showed a greater area of new bone formation than the
other 2 groups at 3 months. Contrary to the results of these
studies, we observed statistically higher NB in the group with
defects ﬁlled with PRFþBCP than the other groups on days 10 and
20. Also, at 40 days, there was relatively similar NB in all 4 defects.
These results prove that PRF is effective in the early stages of
healing. Our results were conﬁrmed by the studies of Zhang et al32
and Choukroun et al.27 Zhang et al32 found no difference in NB and
residual bone substitute between a group receiving only bovine
bone graft (Bio-Oss) and a group receiving PRF in combination
with bovine bone graft 6 months after sinus-lifting surgery.
Choukroun et al27 examined the efﬁcacy of freeze-dried bone
allograft compared with freeze-dried bone allograft combined
with PRF. Histologic evaluation revealed that maturation in the
PRF group at 4 months of healing was similar to that in the control
group at 8 months.Table I
Inﬂammation intensity of 4 groups.
Group 10 days 20 days
Empty 1.5 (0.3) 1.0 (0.0)
PRF 1.0 (0.0) 0
Graft 1.0 (0.6) 0
PRFþgraft 2.0 (0.0) 0.5 (0.3)
PRF, platelet-rich ﬁbrin.
The values are mean (SD). No inﬂammation was observed in any groups at 40 days.Because of ethical reasons, relatively long-term studies have to
be planned for clinical studies as the studies listed above. Although
PRF has longer resorption and remodeling times than the other
described platelet concentrations,33 it has features to similar to
those of natural clotting. Therefore, experimental evaluations
investigating the early stages of healing would be beneﬁcial.
Kim et al34 used TCP, PRFþTCP, and recombinant human bone
morphogenic protein 2 (rhBMP-2)–coated TCP in the augmenta-
tion of the maxillary sinus in rabbits. The animals were killed at
3 days and at 1, 2, 4, 6, and 8 weeks. The PRFþTCP group showed
greater area of bone formation compared with the TCP and the
rhBMP-2–coated TCP groups during the evaluation period. InBCP 0.04
PRFþBCP 0.001
PRF Empty defect 1.0
BCP 0.67
PRFþBCP 0.001
BCP Empty defect 0.04
PRF 0.67
PRFþBCP 0.012
PRFþBCP Empty defect 0.001
PRF 0.001
BCP 0.012
BCP, biphasic calcium phosphate; PRF, platelet-rich ﬁbrin.
Table IV
Residual bone substitute ratios in each group at 10, 20, and 40 days.
BCP PRFþBCP P
10 days 30.8 (3.7) 22.1 (4.9) 0.248
20 days 17.8 (0.4) 19.5 (1.3) 0.245
40 days 11.6 (0.8) 10.9 (0.8) 0.661
BCP, biphasic calcium phosphate; PRF, platelet-rich ﬁbrin.
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blood structure similar to that in humans, which allowed creation
of sufﬁcient defect capacity that would be clinically encountered
and a histological examination to be conducted, especially in the
ﬁrst phases of recovery. Therefore, this study used the same PRF
preparation technique as that used in humans.Conclusions
Within the limitations of this experimental study, it can be
concluded that PRF in addition to BCP may favor the formation of
new bone. The effectiveness of PRF depends not only on its
features but also the properties of coadministered grafting mate-
rial. Although it is reported that PRF dissolves more slowly than
other platelet concentrates, it does not exceed months when the
clinical samples only can be collected; therefore, further experi-
mental studies are necessary to investigate the effects of PRF and
coadministered biomaterials on bone healing.Acknowledgments
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